| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-10-01 | EBI-005 | moderate to severe allergic conjunctivitis |
2 | Eleven Biotherapeutics (USA - MA) | Allergic diseases - Immunological diseases - Ophtalmological diseases |
| 2014-09-30 | peripheral arterial disease (PAD) |
Covidien (Ireland) | Cardiovascular diseases | ||
| 2014-09-30 | MelCancerVac® | colorectal cancer | 3 | DanDrit Biotech (Denmark) DanDrit Biotech USA (USA - VT) | Cancer - Oncology |
| 2014-09-30 | RTA 408 ( N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoropropanamide) | Friedreich\'s ataxia |
2 | Reata Pharmaceuticals (USA - CA) | Rare diseases - Neurodegenerative diseases |
| 2014-09-30 | RTA 408 ( N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoropropanamide) | mitochondrial myopathies |
2 | Reata Pharmaceuticals (USA - CA) | Rare diseases - Neuromuscular diseases |
| 2014-09-30 | AVI-7100 | influenza |
1 | Sarepta Therapeutics (USA - MA) | Infectious diseases |
| 2014-09-30 | dupilumab | chronic sinusitis with nasal polyps | 2 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Inflammatory diseases |
| 2014-09-30 | gevokizumab | Behcet\'s disease uveitis |
2 | Xoma (USA - CA) Laboratoires Servier (France) | Rare diseases - Ophtalmological diseases - Inflammatory diseases |
| 2014-09-30 | glembatumumab vedotin | breast cancer |
1,2 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology |
| 2014-09-30 | glembatumumab vedotin | metastatic melanoma |
Celldex Therapeutics (USA - NJ) | Cancer - Oncology | |
| 2014-09-30 | Aricept® (donepezil hydrochloride) | severe Alzheimer\'s disease |
3 | Eisai (Japan) | Neurodegenerative diseases |
| 2014-09-29 | AP26113 | advanced non-small cell lung cancer | 1-2 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2014-09-29 | tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) | renal cell carcinoma | 2 | Aveo Oncology (USA - MA) | Cancer - Oncology |
| 2014-09-29 | VeriStrat® | non-small cell lung cancer |
Aveo Oncology (USA - MA) Biodesix (USA - CO) | Cancer - Oncology | |
| 2014-09-29 | Keytruda® (pembrolizumab) | PD-L1 positive, advanced urothelial cancer (also known as bladder cancer) | 1b | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2014-09-29 | NGP 555 | Alzheimer’s disease |
NeuroGenetic Pharmaceuticals (USA - CA) | Neurodegenerative diseases | |
| 2014-09-29 | tarextumab (anti-Notch2/3, OMP-59R5) | pancreatic cancer | 1b | OncoMed Pharmaceuticals (USA - CA) GSK (UK) | Cancer - Oncology |
| 2014-09-29 | CGEN-15001 | preclinical | Compugen (Israel) | Autoimmune diseases | |
| 2014-09-29 | Tafinlar® (dabrafenib) | metastatic melanoma with BRAF V600 mutations |
3 | GSK (UK) | Cancer - Oncology |
| 2014-09-29 | MPDL3280A (atezolizumab) | metastatic urothelial bladder cancer | 1 | Roche (Switzerland) | Cancer - Oncology |
